PF-Atlas › Clinical Trials › NCT00063869
Study Evaluating the Safety and Efficacy of Etanercept in Patients With Idiopathic Pulmonary Fibrosis
Etanercept · Phase 2
Registry ID
NCT00063869
Phase
Phase 2
Status
Completed
Drug / intervention
Etanercept
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Enrollment
88
About this trial
The objective of the study is to evaluate the safety and efficacy of etanercept in comparison with placebo in a double-blind, parallel, randomized fashion in subjects with idiopathic pulmonary fibrosis (IPF) who failed previous therapy. The treatment period will be up to 1 year. The primary objective is evaluation of safety and efficacy. Secondary: The secondary objective is to evaluate quality of life (QoL) and pharmacokinetics (PK).
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT00063869 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.